Peginterferon-A_2B plus ribavirin is more effective thanpeginterferon-A_2A plus ribavirin in menopausal womenwith chronic hepatitis C

Marco Enea, Calogero Camma', Ranka Vukotic, Stefano Gitto, Aimilia Karampatou, Erica Villa, Vignoli, Ferrari, Alfredo Di Leo, Maria Rendina, Nicola De Maria, Barbara Lei, Luisa Losi, Antonio Francavilla, Veronica Bernabucci

Risultato della ricerca: Article

10 Citazioni (Scopus)

Abstract

Under-enrolment of women to randomized clinical trials, including chronic hepatitis C, has long been recognized. The aim of this study was to identify factors predictive of sustained virological response (SVR) to PEG IFN/Ribavirin antiviral therapy in relation to gender and reproductive status of female patients involved. Seven hundred and forty-six treatment-naïve patients (431 men, 315 women) treated with Peg-IFNα-2a (180 μg/week) or Peg-IFNα-2b (1.5 μg/kg/week) plus ribavirin (800–1400 mg/day) for 24 or 48 weeks were studied between 2006 and 2010. Differences in SVR rate, overall and by gender were assessed after adjustment and propensity score matching. SVR was obtained in 44.2% of Peg-IFNα-2a-treated patients and in 51.2% of Peg-IFNα-2b-treated patients (intention-to-treat; P = 0.139). Age, fibrosis stage and genotype 2 and 3 were independently associated with SVR by multivariate analysis. Analysing by gender, the difference in SVR between PEG-IFNα types was not significant in men but highly significant in women (Peg-IFNα-2a:39.1%vs Peg-IFNα-2b:54.4%, P = 0.007). This was attributable to a higher SVR rate with Peg-IFNα-2b in the difficult postmenopausal population (26.9% Peg-IFNα-2a vs 46.0% Peg-IFNα-2b, P = 0.040). In women, absence of menopause, genotype 2 hepatitis C virus infection and use of Peg-IFNα-2b were independently associated with SVR. In conclusion, predictive factors for SVR are different in men and women. Factors differing between genders are menopause, severe steatosis and peg-interferon used. The higher SVR rate with Peg-IFNα-2b in menopausal women is likely attributable to more favourable pharmacokinetics that allows Peg-IFNα-2b to reach visceral fat and oppose the increased cytokine production and enhanced inflammatory status in menopause.
Lingua originaleEnglish
Numero di pagine0
RivistaJournal of Viral Hepatitis
VolumeEarly view
Stato di pubblicazionePublished - 2012

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases
  • Virology

Cita questo

Enea, M., Camma', C., Vukotic, R., Gitto, S., Karampatou, A., Villa, E., Vignoli, Ferrari, Di Leo, A., Rendina, M., De Maria, N., Lei, B., Losi, L., Francavilla, A., & Bernabucci, V. (2012). Peginterferon-A_2B plus ribavirin is more effective thanpeginterferon-A_2A plus ribavirin in menopausal womenwith chronic hepatitis C. Journal of Viral Hepatitis, Early view.